Protein clinical implications

Schellekens H Immunogenicity of therapeutic proteins clinical implications and future prospects. Clin. Ther. (2002) 24 (11) 457-462. 

Schellekens H. Immunogenicity of therapeutic proteins Clinical implications and future prospects. Clin Therapeut. 2002 24(11) 1720-1740. 

B21. Brodie, B. B., Pharmacological and clinical implications of drug transport. In Tr sport Function of Plasma Proteins (P. Desgrez and P. M. De Traverse, eds.), pp. 137-145. Elsevier, Amsterdam, 1966. 

Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW (1993) Biological and clinical implications of heat shock protein 27000 (Hsp27 a review. J Natl Cancer Inst 85 1558-1570... 

Bjarnason, G.A., Jordan, R. Circadian variation of cell proliferation and cell cycle protein expression in man clinical implications. Prog. Cell Cycle Res. 2000, 4 193-206. 

Roberts WL, Moulton L, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods implications for clinical and epidemiological applications. Part 2. Clin Chem 2001 47 418-25. 

Thrombosis and Its Clinical Implications As a normal hemostatic response to limit hemorrhage from microscopic or macroscopic vascular injury, the body undergoes a process termed local thrombosis. Specific proenzymes and proteins, platelets, and calcium participate in this process. The end result is the formation of insoluble fibrin, which mechanically blocks the flow of blood through ruptured vessels.55 Thrombosis is usually counterbalanced by physiological anticoagulation and thrombolysis. Under normal conditions, the thrombus is confined to the area of vessel injury and rarely obstructs flow to critical areas. However,... 

Scheper, R.J., Scheffer, G.L., Jonker, J.W., Smit, J.W., Beijnen, J.H., and Schinkel, A.H. (2000) Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals of the New York Academy of Sciences, 922, 188-194. 

M. D. Ringel, W. F. Schwindinger, and M. A. Levine Clinical implications of genetic defects in G proteins The molecular basis of McCune-Albright... 

Studies on identical and non-identical twins have shown that much interindividual pharmacokinetic variability is determined genetically. Pharmacokinetic variability may be caused by genetic polymorphism (the situation where several functionally distinct genes are common in a population) in genes involved in drug absorption, distribution and elimination. In recent years, several polymorphisms in genes encoding for transporter proteins have been described. These polymorphisms could alter the absorption, distribution and elimination of compounds that are substrates for these transporters. However, much work remains to be done to understand the clinical implications of these polymorphisms. 

Harper AE. 1976. Protein and amino acids in the regulation of food intake. Hunger Basic Mechanisms and Clinical Implications. Novin D, Wyrwicka W, Bray G, editors. New York Raven Press pp. 103-113. 

Seth S and Brittenham GM (2000) Genetic disorders affecting proteins of iron metabolism clinical implications. Annu Rev Med 51 443-464. 

The pyrimidine antihuman immunodeficiency viral compound ( )-2 -deoxy-3 -oxa-4 -thiocytidine (dOTC) is administered as the racemate. In a stereoselective evaluation of the pharmacokinetics of dOTC in 12 healthy volunteers (Table 2) [10], it was found that the CL of the (—) enantiomer was 31% greater than antipode. In contrast, the Vss of the (—) enantiomer was lower than antipode [(- -) (—) ratio of 1.4). Plasma protein binding of dOTC enantiomers was not studied. The authors noted marked secondary peaks for both enantiomers after oral dosing, which was attributed to three absorption processes. The overall oral bioavailability was found to be over 75% for each enantiomer [10]. Nevertheless, because the enantiomers of dOTC have approximately the same level of antiviral activity [10], the stereoselectivity in pharmacokinetics may not have a clinical implication for this drug. 

---